Skip to main content

Table 1 Clinicopathological data and DTC status at BM1 and BM3

From: Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival

Variable Number of patients (N) DTC+ at BM1
n/number assessedd (%)
P-value DTC+ at BM3
n/number assessedd (%)
P-value
Total number 236 49/231 (21.2)   43/162 (26.5)  
Median age, years (range) 51 (25-70)     
cT status:    0.471b   0.659b
   cT0-cT3 187 37/183 (20.2)   36/132 (27.3)  
   cT4 49 12/48 (25.0)   7/30 (23.3)  
cN status    0.654b   0.203b
   cN0 98 19/95 (20.0)   15/69 (21.7)  
   cN1 104 21/103 (20.4)   20/74 (27.0)  
   cN2-4 34 9/33 (27.3)   8/19 (42.1)  
M status    0.162b   0.109ª
   M1 25 8/25 (32.0)   6/13 (46.2)  
   M0 211 41/206 (19.9)   37/149 (24.8)  
Hormone receptor status      
Estrogen receptor    0.332ª   0.816ª
   ER-pos 133 32/131 (24.4)   27/101 (26.7)  
   ER-neg 98 16/95 (16.8)   16/58 (27.6)  
   Unknown 5     
Progesterone receptor    0.072ª   0.478ª
   PgR-pos 113 30/110 (27.3)   26/88 (29.5)  
   PgR-neg 118 18/116 (15.5)   16/71 (22.5)  
   Unknown 5     
Histological grade    0.666b   0.960ª
   Grade 1 14 4/13 (30.8)   3/12 (25.0)  
   Grade 2 98 21/96 (21.9)   20/72 (27.8)  
   Grade 3 110 22/108 (20.4)   18/72 (25.0)  
   Unknown 14     
Response    1.000ª   0.784ª
   Complete response 10 2/10 (20.0)   1/6 (16.7)  
   Partial response 108 22/104 (21.2)   19/79 (24.1)  
   Stable disease 88 18/87 (20.7)   15/61 (24.6)  
   Progression 6 1/6 (16.7)   1/2 (50.0)  
   Unknown 24     
BM1 status (pretreatment)      0.077b
   Positive 49    14/37 (37.8)  
   Negative 182    28/121 (23.1)  
   Unknown 5     
BM2 status (at surgery)    1.000ª   0.654ª
   Positive 11 2/11 (18.2)   1/7 (14.3)  
   Negative 58 9/55 (16.4)   12/38 (31.6)  
   Unknown 167     
BM3 status (at 1 year follow-up)    0.077b   
   Positive 43 14/42 (33.3)    
   Negative 119 23/116(19.8)    
   Unknown 74     
PB1 status (pretreatment)    0.033ª   0.464ª
   Positive 10 5/10 (50.0)   1//2 (50.0)  
   Negative 209 39/204 (19.1)   39/148 (26.4)  
   Unknown 17     
PB2 status (at surgery)    1.000ª   0.298ª
   Positive 1 0/1 (0)   1/1 (100.0)  
   Negative 70 12/67 (17.9)   13/46 (28.2)  
   Unknown 165     
PB3 status (at 1 year follow-up)    0.618ª   0.004ª
   Positive 6 2/6 (33.3)   5/6 (83.3)  
   Negative 135 29/131 (22.1)   30/133 (22.6)  
   Unknown 95     
Relapse c    0.642b   0.005b
   Yes 98 22/98 (22.4)   22/55 (40.0)  
   No 112    21/107 (19.6)  
Relapse type      
   Locoregional only 4 0/4 (0)   0/2 (0)  
   Distant metastases (skeletal and/or visceral) 76 18/74 (24.3)   15/42 (35.7)  
   Distant metastases and locoregional 18 4/18 (22.2)   7/11 (63.6)  
Death and cause e      
   Breast cancer death 106 23/105 (21.9)   26/53 (49.1)  
   Any death 111 25/110 (22.7)   27/57 (47.4)  
   Alive 124 24/120 (20.0)   16/105 (15.2)  
  1. ªP-value computed by Fisher's exact test. bP-value computed by Pearson Chi-square. cRelapse data only for M0. dThe denominator (number assessed) for all fractions in the table represents the number of patients with known DTC status (positive or negative) for the respective parameter. eNo information available from one patient due to non-adherence.cT: clinical tumor status, cN: clinical lymph node status, M status: metastases status, DTC: disseminated tumor cells, BM: bone marrow, PB: peripheral blood.